Loading
The lutetium used in approved prostate and neuroendocrine cancer treatments is made from an enriched metal that comes mostly from Russia. Making it elsewhere would secure supply.
No-carrier-added lutetium-177 is produced by irradiating enriched ytterbium-176, most of which has historically come from Russian electromagnetic separators. Demand is rising steeply with Pluvicto, Lutathera and pipeline radioligands. Several companies (ASP Isotopes, ITM, SHINE and others) are developing laser or centrifuge enrichment in North America and Europe. The proposal is an advance market commitment by health systems and manufacturers to buy a guaranteed volume of Western-enriched ytterbium-176 at a floor price for ten years, with a strategic buffer stock, mirroring how vaccine advance commitments created capacity.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, Manufacturing cost and time for living and radioactive medicines.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, Novartis.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, Radioligand therapy (beta emitters).
Shares Manufacturing cost and time for living and radioactive medicines, Radioligand therapy (beta emitters), Most of the world has almost no cancer care.
Shares Lutetium-177 dotatate, Radioligand therapy (beta emitters), Novartis.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, Most of the world has almost no cancer care.
Shares Lutetium-177 vipivotide tetraxetan, Radioligand therapy (beta emitters), Novartis.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines.